Get started
Author

Kelli Glenn

Observed names: Kelli J. Glenn, Kelli J. Glenn
ORCID: 0000-0003-2874-5218
Observed ORCID: 0000-0003-2874-5218
OpenAlex ID: A5067154728
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
2013 · Qingjie Ding, Zhuming Zhang, et al. · Journal of Medicinal Chemistry · 587
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
2013 · Binh Vu, Peter Wovkulich, et al. · ACS Medicinal Chemistry Letters · 389
Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties
2009 · Leopoldo Luistro, Wei He, et al. · Cancer Research · 191
Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate
2020 · Ramesh Sharma, Michiko Nakamura, et al. · European Journal of Pharmacology · 134
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development
2013 · Zhuming Zhang, Xin-Jie Chu, et al. · ACS Medicinal Chemistry Letters · 88
Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
2013 · Camelia Iancu-Rubin, Goar Mosoyan, et al. · Experimental Hematology · 88
Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
2014 · Brian Higgins, Kelli Glenn, et al. · Clinical Cancer Research · 63
PDF
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy
2014 · Zhuming Zhang, Qingjie Ding, et al. · Bioorganic & Medicinal Chemistry · 58
Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors
2013 · Kevin Anderson, Yi Chen, et al. · Bioorganic & Medicinal Chemistry Letters · 56
Effect of cenobamate on the single‐dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects
2021 · Stephen A. Greene, Charles Kwak, et al. · Clinical and Translational Science · 43
Mass Balance, Metabolism, and Excretion of Cenobamate, a New Antiepileptic Drug, After a Single Oral Administration in Healthy Male Subjects
2020 · Laurent Vernillet, Stephen A. Greene, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 34
Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
2015 · Neil L. Spector, Faith C. Robertson, et al. · PLoS ONE · 30
PDF
Anticonvulsant effects of cenobamate in chemically and electrically induced seizure models in rodents
2023 · Susan M. Melnick, Yujin Shin, et al. · Heliyon · 19
Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers
2016 · Jocelyn Zhou, Michelle Quinlan, et al. · British Journal of Clinical Pharmacology · 17
PDF
Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans
2015 · Kelli J. Glenn, Li J. Yu, et al. · Xenobiotica · 9
Potential of cenobamate as a broad-spectrum antiseizure medication
2025 · Susan M. Melnick, Sunita N Misra, et al. · Expert Opinion on Pharmacotherapy · 7
PDF
Effects of Cenobamate on GABA-A Receptor Modulation (P1.5-033)
2019 · Ramesh Sharma, Woo Seok Song, et al. · Neurology · 6
Abstract B55: Antitumor activity of the MDM2 antagonist RG7388.
2013 · Brian Higgins, Christian Tovar, et al. · Molecular Cancer Therapeutics · 5
Distribution, Metabolism, and Excretion of Cenobamate in Adult, Fetal, Neonatal, and Lactating Rats
2023 · Jairam Palamanda, Kelli J. Glenn, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 4
P154 - Absorption, distribution, metabolism, and excretion of the novel antiepileptic drug cenobamate: mass balance following oral administration in healthy male subjects
2020 · Kelli J. Glenn, Stephen Greene, et al. · Drug Metabolism and Pharmacokinetics · 3
The Cardiac Sodium Channel Safety Profile of Cenobamate at Therapeutic Concentrations: In Vitro Analyses
2025 · William J. Crumb, Susan M. Melnick, et al. · Clinical and Translational Science · 1
PDF
Supplementary Figures 1 - 3, Tables 1 - 2 from Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
2023 · Brian Higgins, Kelli Glenn, et al.
PDF
Supplementary Figures 1 - 3, Tables 1 - 2 from Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
2023 · Brian Higgins, Kelli Glenn, et al.
Data from Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
2023 · Brian Higgins, Kelli Glenn, et al.
Data from Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
2023 · Brian Higgins, Kelli Glenn, et al.
Works count: 33
Citation count: 1,832
H-index: 14
I10-index: 14
Year
Topic
Type